Pharmaceutical Bulk Lansoprazole Powder

CAS:103577-45-3

MF: C16H14F3N3O2S

MW:369.36

EINECS:2017-001-1

Specification: 99% min Lansoprazole Powder

Sample: Lansoprazole Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Lansoprazole Powder Usage and Synthesis.

Lansoprazole is a new type of drug to inhibit gastric acid secretion, it has a significant inhibitory effect on basal gastric acid secretion and gastric acid secretion caused by all stimulants (e.g. histamine, carbamoylcholine, etc.), and its acid inhibitory effect is significantly better than that of H2 receptor blockers, and the degree of inhibition has a clear concentration-dependent relationship.

Lansoprazole in acidic conditions can be rapidly through the wall cell membrane into subsulfonic acid and subsulfonyl derivatives and play a drug effect, on Helicobacter pylori (Hp) has an inhibitory effect, for omeprazole 4 times. Clinically, it is used in the treatment of duodenal ulcer, gastric ulcer, anastomotic ulcer, reflux oesophagitis, and Zollinger-Ellison syndrome (Zollinger-Ellison syndrome; gastrinoma), with remarkable efficacy.

When taking lansoprazole must pay attention to the dosage of the drug, overdose will generally appear mild headache, dizziness, drowsiness, diarrhoea, rash, skin itching; rare poor appetite, fatigue, proteinuria; occasional impotence, anxiety, depression, and myalgia; aminotransferase elevation, total cholesterol elevation, leukopenia, thrombocytopenia, and eosinophilia.

These adverse reactions, instead of having a therapeutic effect, may aggravate the condition and trigger some unknown chain reactions.

Uses and functions of Irbesartan.

It has obvious inhibitory effect on basic gastric acid and gastric acid secretion caused by all stimulants. Lansoprazole is a new generation of proton inhibitor, which acts on the last ring of gastric acid secretion and strongly inhibits gastric acid, and is used for the treatment of duodenal ulcer, reflux oesophagitis and other conditions.

Benzimidazole derivatives, is the second proton pump inhibitor. It is used for reflux oesophagitis, gastric ulcer, duodenal ulcer.

Pharmacological Effects of Lansoprazole Raw.

Lansoprazole, a substituted benzimidazole derivative, is a second proton pump inhibitor. It is converted to an active sulfenamide derivative in the acidic environment of the fine tubules of the cells of the gastric wall, which is attached to the sulfhydryl group of H+-K+-(ATP) adenosine triphosphatase (the final step in the process of gastric acid secretion catalysed by the enzyme H+-K+-ATPase), and so blunts the enzyme H+-K+-ATPase, inhibiting gastric acid secretion regulated by both centrally and peripherally.

It is at least as potent as omeprazole in inhibiting gastric acid secretion. In vivo studies in animal models have shown that this product inhibits gastric acid secretion less effectively than the H2 receptor antagonists ranitidine and famotidine, but as effectively as omeprazole.

Unlike the H2 receptor antagonists, this product inhibits daytime and nighttime gastric acid secretion whether taken in the morning or at night. It also reduces the amount of gastric acid secretion and inhibits the secretion of pepsin and its activity.

It can remove Campylobacter pylori (a bacterium that causes recurrence of peptic ulcer) from the gastric mucosa.

Production method of Bulk Lansoprazole Powder.

To 2,3-dimethylpyridine was added glacial acetic acid and a portion of 30 per cent hydrogen peroxide, which was heated and the remaining hydrogen peroxide was added. At the end of the reaction, the solvent was evaporated under reduced pressure to give compound (I).

It was slowly added to the mixed acid and heated to give the nitration product (II). A solution of trifluoroethanol was reacted under alkaline conditions for several hours, the nitration product (II) was added dropwise and heated to give the substitution product (III).

To the substitution product (III), acetic anhydride and concentrated sulphuric acid were added dropwise and heated.

The solvent was withdrawn under reduced pressure and the residue was added to a solution of methanol, water and sodium hydroxide, adjusted to alkaline and reacted at room temperature. Compound (Ⅳ) was obtained. Compound (Ⅳ) dissolved in chloroform, dropwise dichlorosulfoxide, reflux. The solvent was evaporated under reduced pressure and methanol was added for use. A methanolic solution of 2-mercaptobenzimidazole and sodium methanol was additionally added and refluxed.

After cooling down, the methanol solution to be used was added dropwise and refluxed to obtain compound (V). Compound (V) was dissolved in dichloromethane and slowly dropped into a solution made of hydrogen peroxide, vanadium pentoxide and tert-butanol. At the end of the reaction, 0.5% sodium thiosulfate solution was added with vigorous stirring. Lansoprazole is obtained after treatment.